Compare Neurocrine Biosciences Inc (NBIX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nvidia Corp — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Nvidia Corp trades at $218.07 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 314.4× Neurocrine Biosciences Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NVDA | |
|---|---|---|
Market Cap | $16.76B | $5.27T |
Sector | Health | Technology |
52-Week High | $185.50 | $235.75 |
52-Week Low | $123.10 | $165.17 |
Enterprise Value | $16.78B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
NVIDIA (NVDA) trades at $217.56, down 2.86% over 24 hours, amid a broader tech sell-off. The stock maintains strong fundamentals with Q1 2026 EPS beating estimates at $1.87 and a net income margin of 62.97%. Technical analysis shows a bullish trend with support at $215 and resistance at $222, while RSI indicates neutral momentum.
Outlook remains positive given robust AI-driven revenue growth and a $325.86 analyst price target, but risks include high valuation multiples and competitive pressures. The stock presents a long-term growth opportunity, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
